Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Bartsch, Rupert ^a   Wenzel, Catharina ^a   Pluschnig, Ursula ^a   Hussian, Dagmar ^a   Sevelda, Ursula ^a   Altorjai, Gabriela ^a   Locker, Gottfried J ^a   Mader, Robert ^a   Zielinski, Christoph C ^a   Steger, Guenther G ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; ESTROGEN RECEPTOR; EXEMESTANE; FULVESTRANT; GOSERELIN; LETROZOLE; TAMOXIFEN; TUMOR MARKER; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DRUG DERIVATIVE; ESTRADIOL; MUCIN 1;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; DRUG RESPONSE; FEMALE; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; METASTASIS; PROGNOSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; BLOOD; BREAST TUMOR; CLINICAL TRIAL; INTRAMUSCULAR DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOEMBRYONIC ANTIGEN; DISEASE PROGRESSION; ESTRADIOL; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MIDDLE AGED; MUCIN-1; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 33645793112     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-81     Document Type: Article

References (25)

1. Soletormos G, Nielsen D, Schioler V, Mouridsen H, Dombernowsky P: Monitoring different stages of breast cancer using tumour markers CA 15-3, CEA and TPA. Eur J Cancer 2004, 40:481-486.
2. Given M, Scott M, Mc Grath JP, Given HF: The predictive of tumour markers CA 15-3, TPS and CEA in breast cancer recurrence. Breast 2000, 9:277-280.
3. Massacesi C, Rocchi MB, Marcucci F, Pilone A, Galeazzi M, Bonsignori M: Serum tumor markers may precede instrumental response to chemotherapy in patients with metastatic cancer. Int J Biol Markers 2003, 18:295-300.
4. Cheung KL, Graves CR, Robertson JF: Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat Rev 2000, 26:91-102.
5. Pompecki R, Schroder G, Garbrecht M, Frahm H: [Carcinoembryonic antigens (CEA) in patients with metastatic breast cancer under endocrine and therapeutic treatment (author's transl)]. Dtsch Med Wachenschr 1978, 103:620-622.
6. Cheung KL, Pinder SE, Paish C, Sadozye AH, Chan SY, Evans AJ, Blamey RW, Robertson JF. The role of blood tumor marker measurement (using a biochemical index score and c-erbB2) in directing chemotherapy in metastatic breast cancer. Int J Biol Markers 2000, 15:203-209.
7. Kurebayashi J, Nishimura R, Tanaka K, Kohno N, Kurosumi M, Moriya T, Ogawa Y, Taguchi T: Significance of serum tumor markers in monitoring advanced breast cancer patients treated with systemic therapy: a prospective study. Breast Cancer 2004, 11:389-95.
8. Sonoo H, Kurebayashi J: Serum tumor marker kinetics and the clinical course of patients with advanced breast cancer. Surg Today 1996, 26:250-257.
9. Yildiz M, Oral B, Bozkurt M, Cobaner A. Relationship between bone scintigraphy and tumor markers in patients with breast cancer. Ann Nucl Med 2004, 18:501-5.
10. Curran M, Wiseman L: Fulvestrant. Drugs 2001, 61:807-13.
11. Buzdar AU: A new type of estrogen receptor antagonist for the treatment of advanced breast cancer. Drugs Today (Barc) 2004, 40:751-764.
12. Hyder SM, Stancel GM: Inhibition of progesterone-induced VEGF production in human breast cancer cells by the pure antiestrogen ICI 182,780. Cancer Lett 2002, 181:47-53.
13. Jones SE: Fulvestrant: an estrogen receptor antagonist that downregulates the estrogen receptor. Semin Oncol 2003, 30:14-20.
14. Howell A, Robertson JFR, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein B, Webster A, Morris C: Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002, 20:3396-3403.
15. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, et al.: Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002, 20:3386-3395.
16. Robertson JF, Osborne CK, Howell A, Jones SE, Mauriac L, Ellis M, Kleeberg UR, Come SE, Vergote I, Gertler S, Buzdar A, et al.: Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women - a prospective combined analysis of two multicenter trials. Cancer 2003, 98:229-238.
17. Mauriac L, Pippen JE, Quaresma Albano J, Gertler SZ, Osborne CK: Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. Eur J Cancer 2003, 39:1228-1233.
18. Howell A, Robertson JFR, Abram P, Lichinitser MR, Elledge R, Bajetta E, Watanabe T, Morris C, Webster A, Dimery I, et al.: Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004, 22:1605-1613.
19. Bross PF, Baird A, Chen G, Jee JM, Lostritto RT, Morse DE, Rosario LA, Williams GM, Yang P, Rahman A, Williams G, et al.: Fulvestrant in postmenopausal women with advanced breast cancer. Clin Cancer Res 2003, 9:4309-4317.
20. Robertson JF, Erikstein B, Osborne CK, Pippen J, Come SE, Parker LM, Gertler S, Harrison MP, Clarke DA, et al.: Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer. Clin Phormacokinet 2004, 43:529-538.
21. Howell A: The future of fulvestrant ('Faslodex'). Cancer Treat Rev 2005:26-33.
22. Loprinzi CL, Tormey DC, Rasmussen P, Falkson G, Davis TE, Falkson HC, Chang AY: Prospective evaluation of carcinoembryonic antigen levels and alternating chemotherapeutic regimens in metastatic breast cancer. J Clin Oncol 1986, 4:46-56.
23. Kiang DT, Greenberg LJ, Kennedy BJ: Tumor marker kinetics in the monitoring of breast cancer. Cancer 1990, 65:193-199.
24. Nicolini A, Colombini C, Luciani L, Carpi A, Giuliani L: Evaluation of serum CA 15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients. Br J Cancer 1991, 64:154-158.
25. Sjostrom J, Alfthan H, Joensuu H, Stenman UH, Lundin J, Blomqvist C: Serum tumour markers CA 15-3, TPA, TPS, hCGbeta and TAT1 in the monitoring of chemotherapy response in metastatic breast cancer. Scand J Clin Lab Invest 2001, 61:431-441.